Electrohypersensitivity as a Newly Identified and Characterized Neurologic Pathological Disorder:

How to Diagnose, Treat, and Prevent It
Int J Mol Sci. 2020 Mar; 21(6): 1915.
Published online 2020 Mar 11. doi: 10.3390/ijms21061915
hpathy.com/scientific-research/electrohypersensitivity-as-a-newly-identified-and-characterized-neurologic-pathological-disorder-how-to-diagnose-treat-and-prevent-it/

Dominique Belpomme 1,2,3,* and Philippe Irigaray 1,2

1 Association for Research Against Cancer (ARTAC), 57/59 rue de la Convention, 75015 Paris, France; moc.liamg@catra.ieppilihp
2 European Cancer and Environment Research Institute (ECERI), 1000 Brussels, Belgium
3 Department of Cancer Clinical Research, Paris V University Hospital, 75005 Paris, France
*Correspondence: moc.liamg@emmopleb.tcatnoc

The authors state that electromagnetic hypersensitivity (EHS) is a neurologic pathological disorder which can be diagnosed, treated, and prevented. They also find associations with multiple chemical sensitivity (MCS). They ask the World Health Organization (WHO) to include EHS as a neurologic disorder.

Abstract
Since 2009, we built up a database which presently includes more than 2000 electrohypersensitivity (EHS) and/or multiple chemical sensitivity (MCS) self-reported cases. This database shows that EHS is associated in 30% of the cases with MCS, and that MCS precedes the occurrence of EHS in 37% of these EHS/MCS-associated cases. EHS and MCS can be characterized clinically by a similar symptomatic picture, and biologically by low-grade inflammation and an autoimmune response involving autoantibodies against O-myelin. Moreover, 80% of the patients with EHS present with one, two, or three detectable oxidative stress biomarkers in their peripheral blood, meaning that overall these patients present with a true objective somatic disorder. Moreover, by using ultrasonic cerebral tomosphygmography and transcranial Doppler ultrasonography, we showed that cases have a defect in the middle cerebral artery hemodynamics, and we localized a tissue pulsometric index deficiency in the capsulo-thalamic area of the temporal lobes, suggesting the involvement of the limbic system and the thalamus. Altogether, these data strongly suggest that EHS is a neurologic pathological disorder which can be diagnosed, treated, and prevented. Because EHS is becoming a new insidious worldwide plague involving millions of people, we ask the World Health Organization (WHO) to include EHS as a neurologic disorder in the international classification of diseases.

Keywords: electrohypersensibility, multiple chemical sensitivity, neurologic disease, oxidative stress, melatonin, O-myelin, inflammation, histamine, radiofrequency, extremely low frequency, electromagnetic fields

For the full paper see the link on top. In the paper the following information:

7. Treatment and Prognostic Evolution

There is, at the moment, no recognized standardized treatment of EHS. There are, however, some treatments that could be indicated, on the basis of biological investigations. We showed, for example, that patients with EHS present frequently with a profound deficit in vitamins and trace elements, especially in vitamin D and zinc, which should be corrected 10,11,22. Anti-histaminics should also be used in the case of increased histamine in the blood. Furthermore, antioxidants such as glutathione and, more specifically, anti-nitrosative medications should also be used in case of oxidative/nitrosative stress. Moreover, as exemplified in Figure 5, we showed that natural products such as fermented papaya preparation (FPP) and ginkgo biloba can restore brain pulsatility in the various middle cerebral artery-dependent tissue areas of temporal lobes, thereby improving brain hemodynamics and, consequently, brain oxygenation 33. Since FPP was shown to possess some antioxidant, anti-inflammation, and immune-modulating properties 34,35,36, we recommend the use of this widely available natural product.



Lees verder in de categorie Onderzoeken | Terug naar homepage | Lees de introductie